TORONTO – Microbix Biosystems Inc. (TSX:MBX) announced Monday that it is suing Novartis, accusing the Swiss-based multinational of infringing its proprietary VirusMax technology.
Microbix, a small biotechnology company with headquarters in the Toronto area, filed its complaint in the Eastern District of Texas.
The VirusMax technology is useful for increasing virus yields in egg-based vaccine manufacture, a technology that Microbix president and CEO Vaughn Embro-Pantalony described as “novel” and developed “at significant cost.”
“The technology provides significant efficiencies to the influenza vaccine industry and it benefits the global supply of vaccine,” he said in a statement announcing the legal action.
“We intend to enforce our intellectual property rights surrounding this technology.”